26 search results
Anus
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
A Randomized Phase II Study of De-lntensified ChemoRadiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Colon
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-GI008 : Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Esophagus
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Liver
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Other Digestive Organ
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Pancreas
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
EA2192 : A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Location: Lebanon, St. Johnsbury, VT
Rectum
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
S2107 : Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, micorsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
Location: Lebanon, St. Johnsbury, VT
Small Intestine
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S1922: Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
Stomach
22BRO873 : Adaptive, individualized dosing of 5-fluorouracil-based chemotherapy to improve treatment efficacy while minimizing severe toxicity: Development and evaluation of the FOX regimen
Location: Lebanon, St. Johnsbury, VT
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT
